381 related articles for article (PubMed ID: 12208763)
21. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.
Carson WE; Yu H; Dierksheide J; Pfeffer K; Bouchard P; Clark R; Durbin J; Baldwin AS; Peschon J; Johnson PR; Ku G; Baumann H; Caligiuri MA
J Immunol; 1999 Apr; 162(8):4943-51. PubMed ID: 10202041
[TBL] [Abstract][Full Text] [Related]
22. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression.
Voronov E; Weinstein Y; Benharroch D; Cagnano E; Ofir R; Dobkin M; White RM; Zoller M; Barak V; Segal S; Apte RN
Cancer Res; 1999 Mar; 59(5):1029-35. PubMed ID: 10070959
[TBL] [Abstract][Full Text] [Related]
23. Enhanced in vitro and in vivo cytotoxicity of umbilical cord blood cells against human breast cancer following activation with IL-15 and colony stimulating factors.
Lovgren TR; Tarantolo SR; Evans C; Kuszynski CA; Joshi SS
In Vivo; 2002; 16(6):541-50. PubMed ID: 12494899
[TBL] [Abstract][Full Text] [Related]
24. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
Liepins A; Nowicky JW
Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
[TBL] [Abstract][Full Text] [Related]
25. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.
Street SE; Hayakawa Y; Zhan Y; Lew AM; MacGregor D; Jamieson AM; Diefenbach A; Yagita H; Godfrey DI; Smyth MJ
J Exp Med; 2004 Mar; 199(6):879-84. PubMed ID: 15007091
[TBL] [Abstract][Full Text] [Related]
26. IL-12 induces T helper 1-directed antitumor response.
Tsung K; Meko JB; Peplinski GR; Tsung YL; Norton JA
J Immunol; 1997 Apr; 158(7):3359-65. PubMed ID: 9120294
[TBL] [Abstract][Full Text] [Related]
27. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2.
Wigginton JM; Kuhns DB; Back TC; Brunda MJ; Wiltrout RH; Cox GW
Cancer Res; 1996 Mar; 56(5):1131-6. PubMed ID: 8640772
[TBL] [Abstract][Full Text] [Related]
28. IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice.
Torroella-Kouri M; Keith JC; Ivanova M; Lopez DM
Int J Oncol; 2003 Feb; 22(2):439-48. PubMed ID: 12527946
[TBL] [Abstract][Full Text] [Related]
29. Generation of alloreactive cytotoxic T lymphocytes: production of T cell and macrophage helper factors in addition to IL 1 and IL 2 by peritoneal cells from mice immunized to Listeria monocytogenes.
Finke JH; Sharma SD; Scott JW
J Immunol; 1981 Dec; 127(6):2354-61. PubMed ID: 6795272
[TBL] [Abstract][Full Text] [Related]
30. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
[TBL] [Abstract][Full Text] [Related]
31. Antitumor therapeutic potential of activated human umbilical cord blood cells against leukemia and breast cancer.
Joshi SS; Tarantolo SR; Kuszynski CA; Kessinger A
Clin Cancer Res; 2000 Nov; 6(11):4351-8. PubMed ID: 11106253
[TBL] [Abstract][Full Text] [Related]
32. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory activity of polysaccharides isolated from Strongylocentrotus nudus eggs.
Liu C; Xi T; Lin Q; Xing Y; Ye L; Luo X; Wang F
Int Immunopharmacol; 2008 Dec; 8(13-14):1835-41. PubMed ID: 18834960
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.
Zitvogel L; Tahara H; Robbins PD; Storkus WJ; Clarke MR; Nalesnik MA; Lotze MT
J Immunol; 1995 Aug; 155(3):1393-403. PubMed ID: 7636204
[TBL] [Abstract][Full Text] [Related]
35. Two types of allograft-induced cytotoxic macrophage, one against allografts and the other against syngeneic or allogeneic tumor cells.
Yoneda Y; Tashiro-Yamaji J; Kubota T; Yoshida R
Microbiol Immunol; 2008 Jul; 52(7):349-56. PubMed ID: 18667033
[TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
[TBL] [Abstract][Full Text] [Related]
37. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
Guiducci C; Vicari AP; Sangaletti S; Trinchieri G; Colombo MP
Cancer Res; 2005 Apr; 65(8):3437-46. PubMed ID: 15833879
[TBL] [Abstract][Full Text] [Related]
38. Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression.
Liu K; Caldwell SA; Abrams SI
Cancer Res; 2005 May; 65(10):4376-88. PubMed ID: 15899830
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
40. Use of curcumin to decrease nitric oxide production during the induction of antitumor responses by IL-2.
Song MY; Yim JY; Yim JM; Kang IJ; Rho HW; Kim HS; Yhim HY; Lee NR; Song EK; Kwak JY; Sohn MH; Yim CY
J Immunother; 2011 Mar; 34(2):149-64. PubMed ID: 21304405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
